Regulatory press release11.12.2025, 10.45Diagonal Bio intends to submit a formal application for bankruptcy
Regulatory press release31.10.2025, 08.00Diagonal Bio publishes interim report for the third quarter of 2025
Press release13.10.2025, 09.00Diagonal Bio launches new website to reflect commercial focus on the Animal Health segment
Press release03.10.2025, 11.30Diagonal Bio initiates collaboration with SVA on evaluation of coronavirus in horses
Regulatory press release23.09.2025, 11.15Diagonal Bio expands horse testing panel to detect Equine Herpesvirus type 2
Regulatory press release22.08.2025, 08.00Diagonal Bio publishes interim report for the second quarter of 2025
Press release07.07.2025, 13.00Diagonal Bio AB files patent application for Novel Computational Method that significantly improves LAMP primer design
Regulatory press release25.06.2025, 13.00The Board of Directors of Diagonal Bio carries out a directed issue to underwriters in connection with exercise of warrants of series TO 2
Regulatory press release19.06.2025, 13.40Diagonal Bio receives SEK 3.6 million through exercise of warrants of series TO 2
Regulatory press release17.06.2025, 18.47Update regarding large shareholder’s exercise of warrants of series TO 2
Regulatory press release17.06.2025, 08.30Diagonal Bio expands equine panel with addition of strangles
Regulatory press release13.06.2025, 08.00Last day of trading in Diagonal Bio’s warrants of series TO 2 is 16 June 2025
Regulatory press release09.06.2025, 14.00Svea Bank AB invests SEK 0.5 million in Diagonal Bio AB through the exercise of warrants of series TO 2